Economic Analysis of Granulocyte Colony Stimulating Factor as Adjunct Therapy for Older Patients with Acute Myelogenous Leukemia (AML): Estimates from a Southwest Oncology Group Clinical Trial

L. Bennett, Charles; M. Hynes, Denise; E. Godwin, John; J. Stinson, Tammy; Golub, Robert; R. Appelbaum, Frederick

doi:10.1081/cnv-100104288

Public

Economic Analysis of Granulocyte Colony Stimulating Factor as Adjunct Therapy for Older Patients with Acute Myelogenous Leukemia (AML): Estimates from a Southwest Oncology Group Clinical Trial

Published in Cancer Investigation • Jan 1, 2001

Authors:

Charles L. Bennett

Denise M. Hynes

John E. Godwin

Abstract

Considerable morbidity, mortality, and economic costs result during remission induction therapy for elderly patients with acute myeloid leukemia (AML). In this study, the economic costs of adjunct granulocyte colony stimulating factor (G-CSF) are estimated for AML patients > 55 years of age who rece...

Subject

Medicine

Internal medicine

Placebo

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!